DOE PAGES title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Versatility of the adenovirus-vectored foot-and-mouth disease vaccine platform across multiple foot-and-mouth disease virus serotypes and topotypes using a vaccine dose representative of the AdtA24 conditionally licensed vaccine

Abstract

We investigated the serotype- and topotype versatility of a replication-deficient human adenovirus serotype 5 vectored foot-and-mouth disease (FMD) vaccine platform (AdtFMD). Sixteen AdtFMD recombinant subunit monovalent vaccines targeting twelve distinct FMD virus (FMDV) serotype/topotypes in FMD Regional Pools I-VII were constructed. The AdtA24 serotype conditionally licensed vaccine served as the basis for vaccine design and target dose for cattle clinical trials. Several vaccines contained an additional RGD motif genetic insertion in the adenovector fiber knob, and/or a full-length 2B gene insertion in the FMDV P1 gene cassette. In 13 of the 22 efficacy studies conducted, naïve control and AdtFMD vaccinated cattle were challenged intradermolingually at 2 weeks post-vaccination using a FMDV strain homologous to the AdtFMD vaccine strain. Each of the 16 AdtFMD vaccines were immunogenic based on the presence of homologous neutralizing antibodies in the serum of approximately 90% of total vaccinates (n = 375) on the day of challenge. Importantly, for 75% of vaccines tested, the effective dose that conferred 100% protection against clinical FMD was identical to or in some cases lower than, the minimum protective dose for the conditionally licensed AdtA24 vaccine formulated with ENABL® adjuvant. Results also confirmed the capability of the AdtFMD vaccine platformmore » to differentiate infected from vaccinated animals (DIVA) across the five FMDV serotypes evaluated. Collectively, this comprehensive set of FMD cattle vaccine dose ranging studies highlights the serotype- and topotype versatility of the AdtFMD vaccine platform for further development, licensure, and application in FMD outbreak control and disease eradication efforts.« less

Authors:
 [1];  [1];  [1];  [2]; ORCiD logo [1];  [1];  [3];  [1];  [4];  [1];  [2];  [2];  [1]; ORCiD logo [1]
  1. Plum Island Animal Disease Center, Greenport, NY (United States)
  2. GenVec, Inc., Gaithersburg, MD (United States)
  3. Plum Island Animal Disease Center Research Participation Program, Oak Ridge, TN (United States). Oak Ridge Institute for Science and Education
  4. Plum Island Animal Disease Center, Greenport, NY (United States); Plum Island Animal Disease Center Research Participation Program, Oak Ridge, TN (United States). Oak Ridge Institute for Science and Education
Publication Date:
Research Org.:
Oak Ridge Inst. for Science and Education (ORISE), Oak Ridge, TN (United States)
Sponsoring Org.:
USDOE
OSTI Identifier:
1494688
Grant/Contract Number:  
AC05-06OR23100; HSHQPD-07-X-00003; HSHQDC-14-F-00035; HSHQDC-8-C-00011; HSHQDC-12-C-00127
Resource Type:
Accepted Manuscript
Journal Name:
Vaccine
Additional Journal Information:
Journal Volume: 36; Journal Issue: 48; Journal ID: ISSN 0264-410X
Publisher:
Elsevier
Country of Publication:
United States
Language:
English
Subject:
59 BASIC BIOLOGICAL SCIENCES; 60 APPLIED LIFE SCIENCES; Foot-and-mouth disease virus; Recombinant human adenovirus vectored vaccine; Serotype; Vaccine efficacy; DIVA; Cattle

Citation Formats

Barrera, José, Brake, David A., Schutta, Christopher, Ettyreddy, Damodar, Kamicker, Barbara J., Rasmussen, Max V., Bravo de Rueda, Carla, Zurita, Mariceny, Pisano, Melia, Hurtle, William, Brough, Douglas E., Butman, Bryan T., Harper, Bruce G., and Neilan, John G. Versatility of the adenovirus-vectored foot-and-mouth disease vaccine platform across multiple foot-and-mouth disease virus serotypes and topotypes using a vaccine dose representative of the AdtA24 conditionally licensed vaccine. United States: N. p., 2018. Web. doi:10.1016/j.vaccine.2018.10.031.
Barrera, José, Brake, David A., Schutta, Christopher, Ettyreddy, Damodar, Kamicker, Barbara J., Rasmussen, Max V., Bravo de Rueda, Carla, Zurita, Mariceny, Pisano, Melia, Hurtle, William, Brough, Douglas E., Butman, Bryan T., Harper, Bruce G., & Neilan, John G. Versatility of the adenovirus-vectored foot-and-mouth disease vaccine platform across multiple foot-and-mouth disease virus serotypes and topotypes using a vaccine dose representative of the AdtA24 conditionally licensed vaccine. United States. https://doi.org/10.1016/j.vaccine.2018.10.031
Barrera, José, Brake, David A., Schutta, Christopher, Ettyreddy, Damodar, Kamicker, Barbara J., Rasmussen, Max V., Bravo de Rueda, Carla, Zurita, Mariceny, Pisano, Melia, Hurtle, William, Brough, Douglas E., Butman, Bryan T., Harper, Bruce G., and Neilan, John G. Sat . "Versatility of the adenovirus-vectored foot-and-mouth disease vaccine platform across multiple foot-and-mouth disease virus serotypes and topotypes using a vaccine dose representative of the AdtA24 conditionally licensed vaccine". United States. https://doi.org/10.1016/j.vaccine.2018.10.031. https://www.osti.gov/servlets/purl/1494688.
@article{osti_1494688,
title = {Versatility of the adenovirus-vectored foot-and-mouth disease vaccine platform across multiple foot-and-mouth disease virus serotypes and topotypes using a vaccine dose representative of the AdtA24 conditionally licensed vaccine},
author = {Barrera, José and Brake, David A. and Schutta, Christopher and Ettyreddy, Damodar and Kamicker, Barbara J. and Rasmussen, Max V. and Bravo de Rueda, Carla and Zurita, Mariceny and Pisano, Melia and Hurtle, William and Brough, Douglas E. and Butman, Bryan T. and Harper, Bruce G. and Neilan, John G.},
abstractNote = {We investigated the serotype- and topotype versatility of a replication-deficient human adenovirus serotype 5 vectored foot-and-mouth disease (FMD) vaccine platform (AdtFMD). Sixteen AdtFMD recombinant subunit monovalent vaccines targeting twelve distinct FMD virus (FMDV) serotype/topotypes in FMD Regional Pools I-VII were constructed. The AdtA24 serotype conditionally licensed vaccine served as the basis for vaccine design and target dose for cattle clinical trials. Several vaccines contained an additional RGD motif genetic insertion in the adenovector fiber knob, and/or a full-length 2B gene insertion in the FMDV P1 gene cassette. In 13 of the 22 efficacy studies conducted, naïve control and AdtFMD vaccinated cattle were challenged intradermolingually at 2 weeks post-vaccination using a FMDV strain homologous to the AdtFMD vaccine strain. Each of the 16 AdtFMD vaccines were immunogenic based on the presence of homologous neutralizing antibodies in the serum of approximately 90% of total vaccinates (n = 375) on the day of challenge. Importantly, for 75% of vaccines tested, the effective dose that conferred 100% protection against clinical FMD was identical to or in some cases lower than, the minimum protective dose for the conditionally licensed AdtA24 vaccine formulated with ENABL® adjuvant. Results also confirmed the capability of the AdtFMD vaccine platform to differentiate infected from vaccinated animals (DIVA) across the five FMDV serotypes evaluated. Collectively, this comprehensive set of FMD cattle vaccine dose ranging studies highlights the serotype- and topotype versatility of the AdtFMD vaccine platform for further development, licensure, and application in FMD outbreak control and disease eradication efforts.},
doi = {10.1016/j.vaccine.2018.10.031},
journal = {Vaccine},
number = 48,
volume = 36,
place = {United States},
year = {2018},
month = {10}
}

Journal Article:
Free Publicly Available Full Text
Publisher's Version of Record

Citation Metrics:
Cited by: 2 works
Citation information provided by
Web of Science

Figures / Tables:

Table 1 Table 1: Replication deficient AdtFMD vaccine constructs evaluated for cattle efficacy.

Save / Share:

Works referenced in this record:

Foot-and-Mouth Disease Impact on Smallholders - What Do We Know, What Don't We Know and How Can We Find Out More?
journal, May 2016

  • Knight-Jones, T. J. D.; McLaws, M.; Rushton, J.
  • Transboundary and Emerging Diseases, Vol. 64, Issue 4
  • DOI: 10.1111/tbed.12507

Global Foot-and-Mouth Disease Research Update and Gap Analysis: 2 - Epidemiology, Wildlife and Economics
journal, June 2016

  • Knight-Jones, T. J. D.; Robinson, L.; Charleston, B.
  • Transboundary and Emerging Diseases, Vol. 63
  • DOI: 10.1111/tbed.12522

The need for improved vaccines against foot-and-mouth disease
journal, April 2018


Use of ENABL® adjuvant to increase the potency of an adenovirus-vectored foot-and-mouth disease virus serotype A subunit vaccine
journal, February 2018


Safety profile of a replication-deficient human adenovirus-vectored foot-and-mouth disease virus serotype A24 subunit vaccine in cattle
journal, October 2017

  • Barrera, J.; Brake, D. A.; Kamicker, B. J.
  • Transboundary and Emerging Diseases, Vol. 65, Issue 2
  • DOI: 10.1111/tbed.12724

A gene transfer vector-cell line system for complete functional complementation of adenovirus early regions E1 and E4
journal, September 1996


A Continuous Bovine Kidney Cell Line Constitutively Expressing Bovine  V 6 Integrin Has Increased Susceptibility to Foot-and-Mouth Disease Virus
journal, March 2013

  • LaRocco, M.; Krug, P. W.; Kramer, E.
  • Journal of Clinical Microbiology, Vol. 51, Issue 6
  • DOI: 10.1128/JCM.03370-12

Use of a portable real-time reverse transcriptasepolymerase chain reaction assay for rapid detection of foot-and-mouth disease virus
journal, June 2002

  • Callahan, Johnny D.; Brown, Fred; Osorio, Fernando A.
  • Journal of the American Veterinary Medical Association, Vol. 220, Issue 11
  • DOI: 10.2460/javma.2002.220.1636

Multimodel Inference: Understanding AIC and BIC in Model Selection
journal, November 2004

  • Burnham, Kenneth P.; Anderson, David R.
  • Sociological Methods & Research, Vol. 33, Issue 2
  • DOI: 10.1177/0049124104268644

Longevity of protection in cattle following immunisation with emergency FMD A22 serotype vaccine from the UK strategic reserve
journal, March 2010


Genetic characterisation of the recent foot-and-mouth disease virus subtype A/IRN/2005
journal, January 2007


Recent Spread of a New Strain (A-Iran-05) of Foot-and-Mouth Disease Virus Type A in the Middle East
journal, June 2009


Foot-and-Mouth Disease Virus Serotype A in Egypt
journal, October 2007

  • Knowles, Nick J.; Wadsworth, Jemma; Reid, Scott M.
  • Emerging Infectious Diseases, Vol. 13, Issue 10
  • DOI: 10.3201/eid1310.070252

Delivery of a foot-and-mouth disease virus empty capsid subunit antigen with nonstructural protein 2B improves protection of swine
journal, October 2008


DetailedAnalysis of the CD8 + T-Cell Response followingAdenovirusVaccination
journal, December 2003


Evaluation of a Fiber-Modified Adenovirus Vector Vaccine against Foot-and-Mouth Disease in Cattle
journal, November 2015

  • Medina, Gisselle N.; Montiel, Nestor; Diaz-San Segundo, Fayna
  • Clinical and Vaccine Immunology, Vol. 23, Issue 2
  • DOI: 10.1128/CVI.00426-15

Protection induced by a commercial bivalent vaccine against Foot-and-Mouth Disease 2010 field virus from Ecuador
journal, July 2016


Review of the Global Distribution of Foot-and-Mouth Disease Virus from 2007 to 2014
journal, May 2015

  • Brito, B. P.; Rodriguez, L. L.; Hammond, J. M.
  • Transboundary and Emerging Diseases, Vol. 64, Issue 2
  • DOI: 10.1111/tbed.12373

Epidemiology of the Foot-and-Mouth Disease Serotype O Epidemic of November 2010 to April 2011 in the Republic Of Korea
journal, June 2013

  • Yoon, H.; Yoon, S. -S.; Kim, Y. -J.
  • Transboundary and Emerging Diseases, Vol. 62, Issue 3
  • DOI: 10.1111/tbed.12109

Protective effects of high-potency FMDV O 1 Manisa monovalent vaccine in cattle challenged with FMDV O/SKR/2010 at 7 or 4 days post vaccination
journal, September 2017


Experimental infections using the foot-and-mouth disease virus O/JPN/2010 in animals administered a vaccine preserved for emergency use in Japan
journal, January 2017

  • Fukai, Katsuhiko; Nishi, Tatsuya; Shimada, Nobuaki
  • Journal of Veterinary Medical Science, Vol. 79, Issue 1
  • DOI: 10.1292/jvms.16-0482

Adenovirus-vectored foot-and-mouth disease vaccine confers early and full protection against FMDV O1 Manisa in swine
journal, February 2017


Retrospective evaluation of foot-and-mouth disease vaccine effectiveness in Turkey
journal, April 2014


Emergence of Foot-and-Mouth Disease Virus SAT 2 in Egypt During 2012
journal, October 2012

  • Ahmed, H. A.; Salem, S. A. H.; Habashi, A. R.
  • Transboundary and Emerging Diseases, Vol. 59, Issue 6
  • DOI: 10.1111/tbed.12015

An improved, rapid competitive ELISA using a novel conserved 3B epitope for the detection of serum antibodies to foot-and-mouth disease virus
journal, June 2018

  • Chung, Chungwon J.; Clavijo, Alfonso; Bounpheng, Mangkey A.
  • Journal of Veterinary Diagnostic Investigation, Vol. 30, Issue 5
  • DOI: 10.1177/1040638718779641

Works referencing / citing this record:

Biological Function and Application of Picornaviral 2B Protein: A New Target for Antiviral Drug Development
journal, June 2019

  • Li, Zengbin; Zou, Zixiao; Jiang, Zeju
  • Viruses, Vol. 11, Issue 6
  • DOI: 10.3390/v11060510

Figures/Tables have been extracted from DOE-funded journal article accepted manuscripts.